Filing summary
Entity mismatch: The provided filing is IKONICS Corporation’s Form 10-Q, not a TeraWulf Inc. filing. The summary below reflects the filing’s actual contents.
Business context and reporting period
Unaudited quarterly report for the three and nine months ended September 30, 2016, filed November 14, 2016. IKONICS operated five reportable segments: Domestic, Export, IKONICS Imaging, Digital Texturing (DTX), and Advanced Material Solutions (AMS). Interim results are not necessarily indicative of full-year results.
Financial performance and liquidity
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Net sales | $4.608 million | $4.543 million | $12.817 million | $12.794 million |
| Gross profit / margin | $1.667 million / 36.2% | $1.618 million / 35.6% | $4.486 million / 35.0% | $4.358 million / 34.1% |
| Operating income (loss) | $160,000 | $189,000 | $(111,000) | $(87,000) |
| Net income (loss) | $82,000 | $117,000 | $(71,000) | $(84,000) |
| Operating cash flow | Not provided for quarter | Not provided for quarter | $804,000 | $797,000 |
Q3 SG&A was $1.358 million, up from $1.270 million; R&D was $150,000, down from $158,000. Nine-month SG&A rose to $4.122 million from $3.939 million, while R&D declined to $475,000 from $506,000. Interest expense was $22,000 for Q3 and $37,000 for the first nine months, versus none in 2015.
At September 30, cash was $917,000 and short-term investments were $3.399 million, compared with $2.248 million cash and no short-term investments at year-end 2015. Current assets were $8.800 million and current liabilities $1.233 million. Nine-month investing cash outflow was $5.370 million, principally reflecting purchases of certificates of deposit and capital expenditures; financing provided $3.234 million. Cash declined by $1.331 million over the period.
Debt arose from a $3.415 million tax-exempt industrial revenue bond financing for the AMS facility expansion. At quarter-end, scheduled principal was $3.370 million before unamortized issuance costs; the balance-sheet carrying amount was approximately $3.236 million. The loan bears 2.14% stated interest (2.77% effective including debt costs), requires monthly payments of about $18,000, and matures in 2041. Bondholders may tender the bonds in 2021. The company also had an unused $2.050 million asset-secured line of credit expiring May 31, 2017.
Material changes versus comparable periods
- Q3 sales increased 1.4%; AMS sales rose 63.6% and Domestic sales 2.9%, while Export sales fell 6.9% and IKONICS Imaging sales declined 1.5%.
- Nine-month sales were essentially flat. AMS sales increased 94.2% and IKONICS Imaging rose 7.9%; declines in Export (9.2%), Domestic (2.5%), and DTX (20.5%) offset those gains.
- Gross margin improved in both comparisons, attributed to sales mix, higher AMS volumes, and lower raw-material costs. Nine-month operating loss widened, as higher SG&A more than offset the gross-profit increase.
- The company completed a 27,300-square-foot facility expansion for AMS and related equipment, financed in part by the new bond loan. Nine-month capital expenditures for property and equipment were $1.966 million.
Outlook, risks, and unusual items
Management said it planned to continue R&D, product development, technology alliances, DTX initiatives, and international market development. It described AMS as experiencing rapid growth, cited two long-term agreements with major aerospace companies, and said it was negotiating a third. The filing gives no quantified revenue or earnings guidance. Management expected approximately $60,000 of additional 2016 capital expenditures and said it believed available resources and financing capacity would fund anticipated operations.
Risks and considerations include the debt-service coverage covenant requiring at least 1.25-to-1.00 on a rolling four-quarter basis; the 2021 bond tender provision; weaker Export demand and a strong U.S. dollar; and AMS’s negative segment operating results despite sales growth. The company reported no legal proceedings or off-balance-sheet arrangements. Disclosure controls were assessed as effective, with no material change in internal control over financial reporting reported.
Most important facts to verify
- Confirm issuer identity: this source is IKONICS Corporation, not TeraWulf Inc.
- Review the debt agreement, especially the 1.25 coverage covenant, 2021 tender provision, collateral, and repayment terms.
- Assess whether AMS growth and the new facility can improve segment profitability; AMS reported a Q3 operating loss of $222,000 and a nine-month loss of $668,000.
- Track Export and DTX demand, international exposure, and the effect of currency strength.
- Reconcile cash usage and capital spending, including the $3.399 million certificates of deposit and completed facility expansion.